Cargando…
Clinical Study on the Melarsoprol-Related Encephalopathic Syndrome: Risk Factors and HLA Association
Melarsoprol administration for the treatment of late-stage human African trypanosomiasis (HAT) is associated with the development of an unpredictable and badly characterized encephalopathic syndrome (ES), probably of immune origin, that kills approximately 50% of those affected. We investigated the...
Autores principales: | Seixas, Jorge, Atouguia, Jorge, Josenando, Teófilo, Vatunga, Gedeão, Miaka Mia Bilenge, Constantin, Lutumba, Pascal, Burri, Christian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7157710/ https://www.ncbi.nlm.nih.gov/pubmed/31906333 http://dx.doi.org/10.3390/tropicalmed5010005 |
Ejemplares similares
-
High Failure Rates of Melarsoprol for Sleeping Sickness, Democratic Republic of Congo
por: Robays, Jo, et al.
Publicado: (2008) -
Safety and Efficacy of the 10-Day Melarsoprol Schedule for the Treatment of Second Stage Rhodesiense Sleeping Sickness
por: Kuepfer, Irene, et al.
Publicado: (2012) -
Trypanosomiasis Control, Democratic Republic of Congo, 1993–2003
por: Lutumba, Pascal, et al.
Publicado: (2005) -
Efficacy, Safety, and Dose of Pafuramidine, a New Oral Drug for Treatment of First Stage Sleeping Sickness, in a Phase 2a Clinical Study and Phase 2b Randomized Clinical Studies
por: Burri, Christian, et al.
Publicado: (2016) -
Neopterin and CXCL-13 in Diagnosis and Follow-Up of Trypanosoma brucei gambiense Sleeping Sickness: Lessons from the Field in Angola
por: Bonnet, Julien, et al.
Publicado: (2019)